Accessibility Menu
CytoMed Therapeutics logo

CytoMed Therapeutics(NASDAQ) GDTC

Market Cap$10.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-77%
5 YearN/A
1 Year-55%
1 Month-2%
$0.91
-1.23%
-0.01Today
CytoMed Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.912026-09-01
CytoMed Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.81%USD 0.942026-08-25
1 month-2.3%USD 0.932026-07-31
3 month-22.99%USD 1.182026-06-03
Year to date-31.93%USD 1.342025-12-31
1 year-54.61%USD 2.002025-08-29
3 year-73.89%USD 3.482023-09-01
Since inception-77.28%USD 4.002023-04-14

CytoMed Therapeutics Financials at a Glance

Market Cap

$10.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

SGD 642.64K

Net Income (TTM)

-SGD 4.85M

EPS (TTM)

-$0.26

P/E Ratio

-3.48

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.91

Volume

169

Open

$0.92

Previous Close

$0.91

Daily Range

$0.76 - $0.92

52-Week Range

$0.68 - $3.68

Estimated Earnings Date

Nov 13, 2026

GDTC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CytoMed Therapeutics

CytoMed Therapeutics Limited is a biopharmaceutical company focused on developing advanced cellular immunotherapies to combat various human malignancies. Founded in 2018 and based in Singapore, the company is currently in the pre-clinical development phase, with innovative products aimed at enhancing cancer treatment.

Products and Services
  • CTM-N2D: Engineered gamma delta T cells targeting cancer cells
  • iPSC-gdNKT: Hybrid cells combining gamma delta T cells and natural killer cells
  • CTM-GDT: Expanded gamma delta T cells for broad-spectrum cancer recognition
Growth Outlook
  • Strong pipeline with multiple investigational products in development
  • Potential for significant market impact in the immunotherapy sector
  • Strategic focus on innovative therapies to address unmet medical needs
Financial Highlights
  • Recent quarterly revenue of 167,945 SGD, showing growth from previous quarters
  • Cash and cash equivalents of 2,095,489 SGD, providing operational stability
  • Current ratio of 5.17, indicating strong liquidity position
CytoMed Therapeutics Limited is positioned in the biotechnology industry, specializing in cutting-edge immunotherapy solutions. The company's lead product, CTM-N2D, utilizes engineered gamma delta T cells to enhance the immune response against cancer. Additionally, the innovative iPSC-gdNKT product aims to combine the strengths of different immune cell types, potentially leading to more effective cancer treatments. The growth outlook for CytoMed is promising, with a robust pipeline of investigational products that could significantly impact the immunotherapy market. The strategic focus on developing therapies for unmet medical needs highlights the company's commitment to addressing critical health challenges. Financially, CytoMed has shown recent revenue growth, with a notable quarterly revenue of 167,945 SGD. The company maintains a strong liquidity position, with cash and cash equivalents totaling 2,095,489 SGD, which supports ongoing research and development efforts. The current ratio of 5.17 further emphasizes the company's ability to meet short-term obligations, indicating a solid foundation for future growth.
AI Generated • Aug 27, 2026

Industry

Biotechnology

Sector

Health Care

Employees

42

CEO

Wee Kiat Tan, PhD

Website

www.cytomed.sg

Headquarters

Singapore, CE 149544, SG

GDTC Financials

Key Financial Metrics (TTM)

Gross Margin

-20.48%

Operating Margin

-672.18%

Net Income Margin

-754.66%

Return on Equity

-70.74%

Return on Capital

-64.32%

Return on Assets

-60.74%

Earnings Yield

-28.74%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$10.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.83M

Volume

169

Avg. Volume

78.67K

Financials (TTM)

Gross Profit

-SGD 131.63K

Operating Income

-SGD 4.32M

EBITDA

-SGD 5.27M

Operating Cash Flow

-SGD 5.38M

Capital Expenditure

-SGD 952.57K

Free Cash Flow

-SGD 6.34M

Cash & ST Invst.

SGD 2.10M

Total Debt

SGD 482.56K

CytoMed Therapeutics Performance Analysis

CytoMed Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31SGD 0N/A
20232023-12-31SGD 0N/A
20242024-12-31SGD 52,006N/A
20252025-12-31SGD 248,269377.4%
CytoMed Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-3188.2%
Q22025-06-300.1%
Q32025-09-3052.0%
Q42025-12-31-18.1%
CytoMed Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31SGD -0.2141420.0%
20232023-12-31SGD -0.2939.5%
20242024-12-31SGD -0.16-43.6%
20252025-12-31SGD -0.2660.3%
CytoMed Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-3126.8%
Q22025-06-30-0.1%
Q32025-09-3022.5%
Q42025-12-31-89.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

SGD 167.95K

+134.7%

Gross Profit

-SGD 555.65K

-544.0%

Gross Margin

-3.31%

N/A

Market Cap

$10.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$256.01K

N/A

Employees

42

N/A

Net Income

-SGD 1.73M

-17.7%

EBITDA

-SGD 2.22M

-237.7%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

SGD 2.10M

-57.8%

Total Debt

SGD 482.56K

+4.2%

Accounts Receivable

SGD 103.86K

+453.1%

Inventory

SGD 1.07M

+27.3%

Long Term Debt

SGD 422.12K

+1.2%

Short Term Debt

SGD 60.45K

+31.7%

Return on Assets

-60.74%

N/A

Return on Invested Capital

-59.37%

N/A

Free Cash Flow

-SGD 2.35M

-129.7%

Operating Cash Flow

-SGD 2.05M

-163.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SONNSonnet BioTherapeutics Holdings, Inc.
$1.26-59.35%
NCNANuCana plc
$1.38-6.12%
XCURExicure, Inc.
$1.30-0.76%
PASGPassage Bio, Inc.
$4.44+0.23%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$14.06+0.06%
NVDANvidia
$217.44-0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.33-0.06%
INTCIntel
$88.97-0.01%

Questions About GDTC

What is the current price of CytoMed Therapeutics?

CytoMed Therapeutics is trading at $0.91 per share.

What is the 52-week range for CytoMed Therapeutics?

Over the past 52 weeks, CytoMed Therapeutics has traded between $0.68 and $3.68.

How much debt does CytoMed Therapeutics have?

As of the most recent reporting period, CytoMed Therapeutics reported total debt of SGD 375.24K.

How much cash does CytoMed Therapeutics have on hand?

CytoMed Therapeutics reported SGD 1.63M in cash and cash equivalents in its most recent financial results.

What is CytoMed Therapeutics’s dividend yield?

CytoMed Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services